Provided by Tiger Trade Technology Pte. Ltd.

Madrigal Pharmaceuticals

516.74
-2.3500-0.45%
Volume:179.83K
Turnover:93.50M
Market Cap:11.91B
PE:-36.35
High:530.67
Open:520.09
Low:514.91
Close:519.09
52wk High:615.00
52wk Low:393.61
Shares:23.06M
Float Shares:13.73M
Volume Ratio:0.65
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.2164
EPS(LYR):-12.8501
ROE:-53.31%
ROA:-17.84%
PB:22.75
PE(LYR):-40.21

Loading ...

Madrigal Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Movement Alert|Madrigal Pharmaceuticals Falls 12.78% in Regular Trading, Q2 Revenue Beats Expectations but Year-over-Year Loss Widens

Market Focus
·
Jul 30

Stock Track | Madrigal Pharmaceuticals Plummets 7.56% in Pre-market as Q2 Loss Widens and Expenses Surge Despite Revenue Beat

Stock Track
·
Jul 30

Movement Alert|Madrigal Pharmaceuticals Falls 6.74% in Pre-Market Trading, Q2 Earnings Beat Estimates but Per-Share Loss Widens Year-Over-Year

Market Focus
·
Jul 30

Alnylam Q2 Revenue Rises 67% on Increased Demand for Amvuttra

Reuters
·
Jul 30

Stock Track | Madrigal Pharmaceuticals Plunges 6.14% in Pre-market as Q2 Loss Widens and Expenses Surge Despite Revenue Growth

Stock Track
·
Jul 30

Madrigal Q2 FY26 Net Loss Widens to $57.9 Million; Net Sales Rise 71% to $364.3 Million

Reuters
·
Jul 30

Madrigal Pharmaceuticals Q2 Product Revenue USD 364.252 Million

Reuters
·
Jul 30

Madrigal Pharmaceuticals Q2 Revenue Rises 71% on Rezdiffra Demand

Reuters
·
Jul 30

Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q2 Net Loss $1.99 a Share, vs. FactSet Est of $2.68 Loss

MT Newswires Live
·
Jul 30

Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate

Benzinga Earnings
·
Jul 30

Madrigal Pharmaceuticals Q2 EPS USD -1.99

THOMSON REUTERS
·
Jul 30

Madrigal Pharmaceuticals Q2 Operating Income USD -56.308 Million

THOMSON REUTERS
·
Jul 30

Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates

THOMSON REUTERS
·
Jul 30

Madrigal Pharmaceuticals Initiated at Overweight by Wells Fargo

Dow Jones
·
Jul 27

Madrigal Pharmaceuticals initiated with an Overweight at Wells Fargo

TIPRANKS
·
Jul 27

Madrigal Pharmaceuticals price target raised to $553 from $542 at BofA

TIPRANKS
·
Jul 22

BofA Securities Adjusts Price Target on Madrigal Pharmaceuticals to $553 From $542

MT Newswires Live
·
Jul 22

Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS

TIPRANKS
·
Jul 22

Madrigal Grants Inducement Equity Awards to 10 New Hires, Sets Option Strike at $550.25

Reuters
·
Jul 22